AED 497.8 million the total profit of Julphar for the second quarter

Julphar announced sales revenue worth AED 799.5 million in the first half of this year, with a growth of 5% compared to the same period of 2014. The company’s financial results, which were shared within the Board of Director’s report, showed a total profit of AED 497.8 million, up 9% yoy.
Julphar reached a new milestone earlier this year for the recombinant Insulin Glargine. In collaboration with one of the leading biopharmaceutical R&D companies in Europe, it succeeded in developing a qualified and well-characterized cell line for the production of Glargine. This was followed by further process development and optimization at pilot scale. 
Julphar also successfully concluded Phase I clinical trial of its Biosimilar Human Insulin, that demonstrated similarity of its investigational biosimilar human insulin compared to the EU-licensed reference product Eli Lilly HUMINSULIN® and has become the first company in the Middle East to have clinical trial filing accepted under the EMA biosimilar guidelines. 
Julphar produces crude insulin using crystals derived from recombinant DNA technology, a state of the art facility that consists of 11 plants at its headquarters in Ras Al Khaimah, as it produces 213 products in different dosage forms and therapeutic areas that are distributed in over 40 countries.
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.